CoChat
Sign Up
Cited by 238PI3K/AKT/mTOR signaling in cancerHead and Neck Cancer StudiesMetabolism, Diabetes, and Cancer

The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.

Mammalian Target of Rapamycin, a Molecular Target in Squamous Cell Carcinomas of the Head and Neck

Amornphimoltham, Panomwat, Patel, Vyomesh, Sodhi, Akrit, Nikitakis, Nikolaos G., Sauk, John J., Sausville, Edward A., Molinolo, Alfredo A., Gutkind, J. Silvio·2005·Cancer Research
DOI 10.1158/0008-5472.can-05-0921
Open this paper in CoChat — free account

Abstract

Emerging knowledge on how the dysregulated function of signaling networks contributes to the malignant growth of squamous cell carcinoma of the head and neck (HNSCC) can now be exploited to identify novel mechanism-based anticancer treatments. In this regard, we have observed that persistent activation of the serine/threonine kinase Akt is a frequent event in HNSCC, and that blockade of its upstream kinase, 3'-phosphoinositide-dependent kinase 1, potently inhibits tumor cell growth. Akt promotes cell proliferation by its ability to coordinate mitogenic signaling with energy- and nutrient-sensing pathways that control protein synthesis through the atypical serine/threonine kinase, mammalian target of rapamycin (mTOR). This kinase, in turn, phosphorylates key eukaryotic translation regulators, including p70-S6 kinase and the eukaryotic translation initiation factor, 4E binding protein 1. Indeed, we show here that aberrant accumulation of the phosphorylated active form of S6, the most downstream target of the Akt-mTOR-p70-S6 kinase pathway, is a frequent event in clinical specimens from patients with HNSCC and their derived cell lines. Of interest, this enhanced level of the phosphorylated active form of S6 was rapidly reduced in HNSCC cell lines and HNSCC xenograft models at clinically relevant doses of rapamycin, which specifically inhibits mTOR. Furthermore, we observed that rapamycin displays a potent antitumor effect in vivo, as it inhibits DNA synthesis and induces the apoptotic death of HNSCC cells, ultimately resulting in tumor regression. These findings identify the Akt-mTOR pathway as a potential therapeutic target for HNSCC, and may provide the rationale for the early clinical evaluation of rapamycin and its analogues in patients with HNSCC.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-05-0921

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 63 references

Cited by

Sorted by citations

Items 101–200 of 238

Related

See all

Metadata

Authors
Amornphimoltham, P., Patel, V., Sodhi, A., Nikitakis, N. G., Sauk, J. J., Sausville, E. A., Molinolo, A. A., & Gutkind, J. S.
Affiliations
  • National Institutes of Health (US)
  • University of Maryland, Baltimore (US)
ORCID
Venue
Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2005-11-01
Volume
65
Issue
21
Pages
9953-9961
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
DOI
10.1158/0008-5472.can-05-0921
OpenAlex
W2115100370
Cited by
238
References
63
Citations by year
2026: 1 · 2025: 2 · 2024: 7 · 2023: 14 · 2022: 4 · 2021: 6 · 2020: 6 · 2019: 7 · 2018: 7 · 2017: 10 · 2016: 20 · 2015: 14 · 2014: 14 · 2013: 13 · 2012: 27
FWCI
4.11
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
mammalian target of rapamycin, mTOR, head and neck squamous cell carcinoma, Akt signaling, p70 S6 kinase, 4E-binding protein 1, rapamycin, PI3K/AKT/mTOR pathway, translational regulation, apoptosis, cancer therapy, 3-phosphoinositide-dependent kinase 1
MeSH terms
Animals, Antibiotics, Antineoplastic, Carcinoma, Squamous Cell, DNA, Neoplasm, Female, Head and Neck Neoplasms, Humans, Mice, Nude, Phosphorylation, Protein Kinases, Signal Transduction, Apoptosis, Phosphatidylinositol 3-Kinases, Sirolimus, Xenograft Model Antitumor Assays, Ribosomal Protein S6 Kinases, 70-kDa, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, Mice, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review